Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 1;12(4):59.
doi: 10.21037/atm-23-421. Epub 2023 Mar 2.

COSMIC-312, a disappointing result-is that so surprising?

Xavier Adhoute  1 , Marc Bourlière  1 , Rodolphe Anty  2
Affiliations
Editorial

COSMIC-312, a disappointing result-is that so surprising?

Xavier Adhoute et al. Ann Transl Med. .
No abstract available

Keywords: Hepatocellular carcinoma (HCC); gene expression; immune checkpoint inhibitor (ICI); tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-421/coif). X.A. reports consulting fees received from Bayer, payments or honoraria from Servier, Ipsen, EISAI, and Bayer to institution, support for attending meetings and/or travel from Ipsen, Milan, Gilead. M.B. reports consulting fees received from Merck-Schering Plow, Gilead, Janssen, Roche, Abbvie and BMS, payments or honoraria from Vertex Boehringer-Ingelheim and GSK, and support for attending meetings and/or travel from Gilead, Roche, Abbvie and BMS. R.A. reports consulting fees received from Bayer, Ipsen, Eisai, Abbvie, MSD, Intercept, payments or honoraria from Gilead, Bayer, Abbvie, and support for attending meetings and/or travel from Gilead and Abbvie. The authors have no other conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61. 10.1126/science.aaa8172 - DOI - PubMed
    1. Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19:222-32. 10.1038/s41590-018-0044-z - DOI - PubMed
    1. O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16:151-67. 10.1038/s41571-018-0142-8 - DOI - PubMed
    1. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. 10.1016/S1470-2045(21)00604-5 - DOI - PubMed
    1. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017;153:812-26. 10.1053/j.gastro.2017.06.007 - DOI - PubMed

LinkOut - more resources